Assuming that PKN3 is the direct target of RhoC in stromal cells, the above reports seem to be consistent with our data showing that PKN3 is involved in potential angiogenic activity and that PKN3 KO in stromal cells inhibits metastasis but not primary tumor growth and in vivo tumor angiogenesis. This evidence concerns the gene RHOC and neoplasm.